Are treatment response assessment maps (TRAMs) and ¹⁸F‐choline positron emission tomography the future of central nervous system lymphoma imaging?

Abstract

8. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States -Badar --Cancer -Wiley Online Library [Internet]. [cited 2020 Nov 16].

Mapping glioma heterogeneity using multiparametric 18F-choline PET/MRI in childhood and teenage-young adults

“…Amino acid tracers have shown higher diagnostic accuracy than MRI in the evaluation of treatment-related changes and treatment response [2]: O -2- 18 F-fluoroethyl-L-tyrosine ( 18 F-FET) uptake is highly increased in grade III/IV gliomas and its dynamic evaluation can help in grading [29], while 3,4-dihydroxy-6- 18 F-fluoro- L -phenylalanine ( 18 F-FDOPA) has demonstrated high potential in defining tumour grade and outcome when combined with DWI and PWI in a paediatric population [14,30]. A recent report described a combined 18 F-choline PET/MRI approach in the evaluation of CNS lymphoma post-treatment [31]; although four of our patients underwent 18 F-choline PET/MRI before surgery secondary to image surveillance, a similar multimodal approach in gliomas offers the potential for improved response assessment in paediatric and TYA gliomas.…”

“…A recent report described a combined 18 F-choline PET/ MRI approach in the evaluation of CNS lymphoma post-treatment [31]; although four of our patients underwent 18 F-choline PET/MRI before surgery secondary to image surveillance, a similar multimodal approach in gliomas offers the potential for improved response assessment in paediatric and TYA gliomas.…”

Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives

“…CCA, formerly termed Treatment Response Assessment Maps (TRAMs) is a novel MRI-based tool that aims to address this challenge. CCA utilises three-dimensional contrast-enhanced T1-weighted imaging to calculate the difference between early and delayed contrast clearance (5 and 60–105 min, respectively) to distinguish active tumor from treatment-related effects or pseudoprogression [ 71 ] (Fig. 7 ).…”

“…7 ). Difference in contrast clearance at these two time points is used to create a colour map where ‘blue’ depicts regions with high contrast clearance due to ‘breakdown of the blood-brain barrier’ (high vascular activity related to active disease) and ‘red’ , to represent sites with low contrast clearance due to an ‘intact blood-brain barrier’ (low vascular activity in non-tumoral tissues) [ 71 , 72 ]. Peker et al compared CCA to standard clinicoradiology follow-up in 37 patients with a total of 130 intracranial metastases and reported a sensitivity of 96.1% and positive predictive value of 99.2% for CCA in determining radiation-effects [ 72 ].…”